Wells Fargo Bullish on Cepheid, Less so on Qiagen and Quidel, as it Initiates Coverage | GenomeWeb

NEW YORK (GenomeWeb) – Wells Fargo Securities today initiated coverage of Cepheid with an Outperform rating, Qiagen with a Market Perform rating, and Quidel also with a Market Perform rating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.